Latest market price
263.81
-3.80-1.42%
News
Down 1.4% — UK approves J&J's oral psoriasis pill (reuters.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | S&P 500, DJIA | P/E | 39.97 | EPS (ttm) | 6.60 | Insider Own | 0.06% | Shs Outstand | 2.41B | Perf Week | 3.23% |
| Market Cap | 635.76B | Forward P/E | 22.75 | EPS next Y | 11.60 | Insider Trans | -18.25% | Shs Float | 2.41B | Perf Month | -2.54% |
| Enterprise Value | 663.18B | PEG | 3.24 | EPS next Q | 2.93 | Inst Own | 68.20% | Short Float | 0.92% | Perf Quarter | -0.80% |
| Income | 16.09B | P/S | 6.40 | EPS this Y | 2.85% | Inst Trans | 0.00% | Short Ratio | 3.16 | Perf Half Y | 15.96% |
| Sales | 99.33B | P/B | 7.80 | EPS next Y | 4.37% | ROA | 8.15% | Short Interest | 22.07M | Perf YTD | 27.48% |
| Book/sh | 33.83 | P/C | 36.90 | EPS next 5Y | 12.34% | ROE | 19.55% | 52W High | 281.07 -6.14% | Perf Year | 36.73% |
| Cash/sh | 7.15 | P/FCF | 30.88 | EPS past 3/5Y | 17.90% 14.89% | ROIC | 15.36% | 52W Low | 184.66 42.86% | Perf 3Y | 72.73% |
| Dividend Est. | 5.36 (2.03%) | EV/EBITDA | 21.53 | Sales past 3/5Y | 5.60% 2.67% | Gross Margin | 68.81% | Volatility | 2.01% 2.07% | Perf 5Y | 63.55% |
| Dividend TTM | 5.28 (2.00%) | EV/Sales | 6.68 | EPS Y/Y TTM | 13.99% | Oper. Margin | 25.70% | ATR (14) | 6.35 | Perf 10Y | 123.08% |
| Dividend Ex-Date | Nov 24, 2026 | Quick Ratio | 0.74 | Sales Y/Y TTM | 11.84% | Profit Margin | 16.20% | RSI (14) | 53.02 | Recom | 2.55 |
| Dividend Gr. 3/5Y | 4.92% 5.25% | Current Ratio | 1.02 | EPS Q/Q | -7.50% | SMA20 | 1.85% | Beta | 0.21 | Target Price | 285.31 |
| Payout | 79.01% | Debt/Eq | 0.59 | Sales Q/Q | 5.86% | SMA50 | -0.52% | Rel Volume | 0.76 | Prev Close | 267.61 |
| Employees | 141,700 | LT Debt/Eq | 0.48 | Earnings | Jan 20 | SMA200 | 7.47% | Avg Volume | 6.98M | Price | 263.81 |
| IPO Date | Jan 02, 1962 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.68% 0.06% | Net Debt/EBITDA | 0.90 | Volume | 5,305,726 | Change | -1.42% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-20-26 | Reiterated | Evercore ISI | $300 | |
| Oct-16-26 | Reiterated | Wells Fargo | Overweight | $275 → $287 |
| Oct-15-26 | Reiterated | Bernstein | Market Perform | $208 → $270 |
| Oct-14-26 | Reiterated | UBS | Buy | $261 → $270 |
| Oct-14-26 | Reiterated | Leerink Partners | Outperform | $265 → $272 |
| Oct-14-26 | Reiterated | Wells Fargo | Overweight | $282 → $275 |
| Oct-14-26 | Reiterated | RBC Capital | Outperform | $290 → $280 |
| Oct-06-26 | Reiterated | RBC Capital | Outperform | $287 → $290 |
| Sep-29-26 | Reiterated | New Street | $278 | |
| Sep-10-26 | Reiterated | HSBC | Buy | $290 → $320 |
Latest News· Times ET
Oct-24-26
Oct-24-2608:54AM
07:00AM
Oct-23-26
08:10AM
UK approves J&J's oral psoriasis pillreuters.com
04:38AM
04:03AM
Oct-22-26
Oct-22-2603:11PM
12:01PM
09:00AM
08:30AM
07:45AM
Oct-21-26
Oct-21-2602:15PM
12:15PM
11:25AM
3 of the Best Value Stocks to Ownyoutube.com
Company
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Ownership
Total institutional ownership68.20%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/28/2025 | FY 2024 12/29/2024 | FY 2023 12/31/2023 | FY 2022 1/1/2023 | FY 2021 1/2/2022 | FY 2020 1/3/2021 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 99,335 | 94,193 | 88,821 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 30,982 | 30,256 | 27,471 | — | — | — | — | — | — | |
| Gross Profit | 68,353 | 63,937 | 61,350 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 25,504 | 23,676 | 21,969 | — | — | — | — | — | — | |
| Research and Development | 16,084 | 14,665 | 17,232 | — | — | — | — | — | — | |
| Other Operating Expense | 1,240 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 25,525 | 25,596 | 22,149 | — | — | — | — | — | — | |
| Interest Expense | 798 | 971 | 755 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -6,990 | 7,956 | -4,707 | — | — | — | — | — | — | |
| Net Income Before Taxes | 17,737 | 32,581 | 16,687 | — | — | — | — | — | — | |
| Income Taxes | 1,642 | 5,777 | 2,621 | — | — | — | — | — | — | |
| Consolidated Net Income | 16,095 | 26,804 | 14,066 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 16,095 | 26,804 | 14,066 | — | — | — | — | — | — | |
| Net Income | 16,095 | 26,804 | 14,066 | — | — | — | — | — | — | |
| EPS (Recurring) | 6.60 | 11.03 | 5.84 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 6.60 | 11.03 | 5.84 | — | — | — | — | — | — | |
| EPS (Diluted) | 6.60 | 11.03 | 5.79 | — | — | — | — | — | — | |
| EBITDA | 30,809 | 41,055 | 24,781 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 39.97 | 18.82 | 25.05 | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.50 | 5.35 | 3.93 | — | — | — | — | — | — | |
| Gross Margin | 68.81 | 67.88 | 69.07 | — | — | — | — | — | — | |
| Operating Margin | 25.70 | 27.17 | 24.94 | — | — | — | — | — | — | |
| Net Margin | 16.20 | 28.46 | 15.84 | — | — | — | — | — | — | |
| Shares Outstanding | 2,448 | 2,429 | 2,407 | — | — | — | — | — | — | |
| Market Capitalization | 645,807 | 504,333 | 349,135 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schmid Timothy | EVP, WW Chair, MedTech | Sep 02 '26 | Option Exercise | 144.99 | 33,597 | 4,871,389 | 47,974 | Sep 04 |
| Schmid Timothy | EVP, WW Chair, MedTech | Sep 02 '26 | Sale | 274.74 | 22,527 | 6,189,068 | 25,447 | Sep 04 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17 '26 | Option Exercise | 115.67 | 15,000 | 1,735,050 | 209,451 | Aug 18 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17 '26 | Sale | 263.36 | 15,000 | 3,950,400 | 194,451 | Aug 18 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13 '26 | Sale | 261.17 | 123,291 | 32,199,927 | 275,967 | Aug 14 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13 '26 | Option Exercise | 115.67 | 123,291 | 14,261,070 | 399,258 | Aug 14 |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 06 '26 | Sale | 257.00 | 15,918 | 4,090,960 | 16,994 | Aug 07 |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 06 '26 | Option Exercise | 131.94 | 9,344 | 1,232,847 | 32,912 | Aug 07 |
| Duato Joaquin | CEO and Chairman of the Board | Aug 05 '26 | Sale | 258.15 | 48,480 | 12,515,010 | 275,967 | Aug 07 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20 '26 | Option Exercise | 130.77 | 23,054 | 3,014,702 | 46,057 | Jul 21 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20 '26 | Sale | 251.27 | 23,054 | 5,792,686 | 23,003 | Jul 21 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11 '26 | Option Exercise | 115.67 | 10,000 | 1,156,700 | 124,288 | Jun 12 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11 '26 | Sale | 241.15 | 10,000 | 2,411,500 | 114,288 | Jun 12 |
| REED JOHN C | EVP, Innovative Medicine, R&D | May 01 '26 | Option Exercise | 0.00 | 25,255 | 0 | 35,913 | May 04 |
| Decker Robert J | VP Corporate Controller | Feb 27 '26 | Option Exercise | 115.67 | 4,075 | 471,355 | 27,757 | Mar 03 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.